Discussing the role of circular RNA in the pathogenesis of non-alcoholic fatty liver disease and its complications.
NAFLD
NASH
circRNA
crosstalk
hepatocellular carcinoma
insulin resistance
liver
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
09
2022
accepted:
17
10
2022
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
23
11
2022
Statut:
epublish
Résumé
Circular RNAs (circRNAs) are class of non-coding RNA, which are characterized by a covalently closed loop structure. Functionally they can act on cellular physiology, notably by sponging microRNAs (miR), regulating gene expression or interacting with binding protein. To date, circRNAs might represent an interesting, underexploited avenue for new target discovery for therapeutic applications, especially in the liver. The first characteristic of non-alcoholic fatty liver disease (NAFLD) is hepatic cholesterol accumulation, followed by its advanced form of the affection, nonalcoholic steatohepatitis (NASH), due to the occurrence of lobular inflammation, irreversible fibrosis, and in some cases hepatocellular carcinoma (HCC). Therefore, studies have investigated the importance of the dysregulation of circRNAs in the onset of metabolic disorders. In this review, we summarize the potential role of circRNAs in the development of metabolic diseases associated with the liver such as NAFLD or NASH, and their potential to become therapeutic strategies for these pathologies.
Identifiants
pubmed: 36407314
doi: 10.3389/fendo.2022.1035159
pmc: PMC9667057
doi:
Substances chimiques
RNA, Circular
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1035159Informations de copyright
Copyright © 2022 Yepmo, Potier, Pinget, Grabarz, Bouzakri and Dumond Bourie.
Déclaration de conflit d'intérêts
J-BP, AG, and KB were employed by ILONOV. J-BP’s thesis is co-funded by an individual financial aid for training through research received by Ilonov from the State, through the Ministry in charge of Research. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Immunol. 2020 Oct;126:31-39
pubmed: 32745796
J Clin Invest. 2005 Feb;115(2):209-18
pubmed: 15690074
Liver Transpl. 2019 May;25(5):695-705
pubmed: 30861321
Nature. 2013 Mar 21;495(7441):384-8
pubmed: 23446346
Semin Cell Dev Biol. 2018 Sep;81:129-140
pubmed: 29183708
Hepatology. 2015 May;61(5):1547-54
pubmed: 25125077
Front Oncol. 2021 May 14;11:667428
pubmed: 34055634
Gastroenterology. 2020 May 18;:
pubmed: 32439497
RNA Biol. 2015;12(4):381-8
pubmed: 25746834
Neirofiziologiia. 1986;18(1):126-9
pubmed: 3960197
Mol Neurobiol. 2015 Dec;52(3):1284-1296
pubmed: 25330936
FASEB J. 2021 Jun;35(6):e21622
pubmed: 33982351
J Obes Metab Syndr. 2022 Mar 30;31(1):17-27
pubmed: 35332111
Int J Mol Sci. 2019 Oct 11;20(20):
pubmed: 31614491
Biomed Res Int. 2017;2017:5936171
pubmed: 28717649
PLoS One. 2012;7(2):e30733
pubmed: 22319583
Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):835-856
pubmed: 34508238
Cell Death Dis. 2020 Dec 14;11(12):1065
pubmed: 33311442
Front Immunol. 2019 Dec 12;10:2893
pubmed: 31921154
Cell Death Dis. 2020 Feb 13;11(2):123
pubmed: 32054840
Front Physiol. 2021 Aug 30;12:710420
pubmed: 34526911
Int J Mol Sci. 2016 May 20;17(5):
pubmed: 27213358
J Lipid Res. 2017 Jan;58(1):247-255
pubmed: 27836992
Dig Liver Dis. 2005 May;37(5):349-56
pubmed: 15843085
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428
pubmed: 31028350
Int J Mol Sci. 2016 Sep 20;17(9):
pubmed: 27657051
Gene. 2020 Mar 20;731:144354
pubmed: 31935513
Front Endocrinol (Lausanne). 2022 Feb 21;13:851520
pubmed: 35265044
Cell Metab. 2006 Sep;4(3):199-210
pubmed: 16950137
Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):627-36
pubmed: 23958599
Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):349-364
pubmed: 29740166
Oxid Med Cell Longev. 2017;2017:3960197
pubmed: 29018509
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238
pubmed: 33349658
J Integr Bioinform. 2019 Jul 13;16(3):
pubmed: 31301674
J Hepatol. 2019 May;70(5):985-998
pubmed: 30711404
Hepatol Commun. 2020 Jan 14;4(4):478-492
pubmed: 32258944
Nature. 1979 Jul 26;280(5720):339-40
pubmed: 460409
Clin Res Hepatol Gastroenterol. 2011 Nov;35(11):709-13
pubmed: 21778132
Mol Endocrinol. 2013 Aug;27(8):1333-42
pubmed: 23782652
Hepatology. 2012 Sep;56(3):1117-28
pubmed: 22407857
J Transl Med. 2020 Dec 11;18(1):476
pubmed: 33308253
Compr Physiol. 2014 Jan;4(1):177-97
pubmed: 24692138
Mol Ther Nucleic Acids. 2021 Jan 16;23:847-862
pubmed: 33614234
Gastroenterology. 2003 Jul;125(1):178-91
pubmed: 12851882
Dig Dis Sci. 2019 Jan;64(1):113-122
pubmed: 30259280
World J Gastroenterol. 2018 Jan 21;24(3):323-337
pubmed: 29391755
Gastroenterology. 2020 May;158(7):1913-1928
pubmed: 32044315
Clin Liver Dis. 2007 Feb;11(1):1-16, vii
pubmed: 17544968
Sci Rep. 2021 Jan 11;11(1):386
pubmed: 33431945
Metabolism. 2016 Aug;65(8):1038-48
pubmed: 26823198
Mol Ther Nucleic Acids. 2020 Aug 14;22:285-297
pubmed: 33230434
Cell Metab. 2019 Jul 2;30(1):157-173.e7
pubmed: 31155494
J Cell Physiol. 2020 Nov;235(11):8270-8282
pubmed: 31960423
Hepatology. 2008 Dec;48(6):1810-20
pubmed: 19030170
Nat Rev Endocrinol. 2022 Aug;18(8):461-472
pubmed: 35534573
Clin Liver Dis (Hoboken). 2013 Mar 29;2(Suppl 1):S4-S7
pubmed: 30992875
World J Gastroenterol. 2014 Nov 14;20(42):15539-48
pubmed: 25400438
Int J Mol Sci. 2021 May 09;22(9):
pubmed: 34065108
Theranostics. 2020 Mar 26;10(11):4851-4870
pubmed: 32308754
Theranostics. 2021 Jan 1;11(6):2755-2769
pubmed: 33456571
Mol Med Rep. 2017 Dec;16(6):7879-7889
pubmed: 28983598
J Hepatol. 2019 Oct;71(4):793-801
pubmed: 31279902
Epigenomics. 2020 Feb;12(3):267-283
pubmed: 31808351
Oncotarget. 2017 Jul 4;8(27):43878-43888
pubmed: 28410211
Oxid Med Cell Longev. 2018 Jun 11;2018:9547613
pubmed: 29991976
Genome Res. 2016 Sep;26(9):1277-87
pubmed: 27365365
Diabetes Care. 2007 May;30(5):1212-8
pubmed: 17277038
Cell. 2020 Oct 1;183(1):76-93.e22
pubmed: 32931733
Nature. 2013 Mar 21;495(7441):333-8
pubmed: 23446348
Cell Physiol Biochem. 2018;45(4):1487-1505
pubmed: 29466788
World J Hepatol. 2017 Apr 18;9(11):533-543
pubmed: 28469809
Curr Hepatol Rep. 2018 Dec;17(4):350-360
pubmed: 31380156
J Biomed Sci. 2019 Apr 25;26(1):29
pubmed: 31027496
Toxicol Lett. 2019 Oct 10;314:89-97
pubmed: 31325635
Hepatobiliary Surg Nutr. 2014 Dec;3(6):344-63
pubmed: 25568859
Mol Med Rep. 2019 Apr;19(4):2636-2648
pubmed: 30720095
Sci Rep. 2021 Jul 22;11(1):14930
pubmed: 34294754
Hepatology. 2006 Nov;44(5):1267-77
pubmed: 17058265
Nutr Metab (Lond). 2021 Feb 23;18(1):22
pubmed: 33622377
Int J Mol Sci. 2022 Jul 13;23(14):
pubmed: 35887082
Vitam Horm. 2007;75:131-59
pubmed: 17368315
Front Physiol. 2019 Mar 19;10:279
pubmed: 30941061
PLoS One. 2014 Mar 07;9(6):e90859
pubmed: 24609083
Growth Factors. 2011 Oct;29(5):196-202
pubmed: 21740331
Front Genet. 2021 Apr 29;12:671523
pubmed: 33995497
Lancet Neurol. 2018 Sep;17(9):802-815
pubmed: 30129476
Cell Death Dis. 2022 May 17;13(5):464
pubmed: 35581180
Hepatology. 2018 May;67(5):2013-2024
pubmed: 29194686
J Hepatol. 1999 Sep;31(3):430-4
pubmed: 10488700
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Front Pharmacol. 2021 Nov 22;12:741151
pubmed: 34887753
Int J Mol Sci. 2022 Jan 18;23(3):
pubmed: 35162956
Hepatology. 2000 Dec;32(6):1248-54
pubmed: 11093731
Cells. 2022 Mar 04;11(5):
pubmed: 35269515
Proc Natl Acad Sci U S A. 1976 Nov;73(11):3852-6
pubmed: 1069269
World J Hepatol. 2015 Apr 28;7(6):846-58
pubmed: 25937862
J Clin Gastroenterol. 2008 Apr;42(4):332-5
pubmed: 18277910
FEBS J. 2022 Jun;289(11):3024-3057
pubmed: 33860630